Center on Health Equity & Access

The complex disparities in pancreatic cancer survival trends across demographics and regions highlight urgent needs for targeted interventions.

Although influenza vaccine uptake remains low, improving access, recommendations, and trust may help close coverage gaps.

Johnson & Johnson partners with the Trump Administration to lower drug prices and utilize TrumpRx.com, joining a growing list of pharmaceutical companies.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

This week, we look at 5 key health care changes the Trump Administration made in 2025, changes to the immunization schedule, and new research on telehealth accessibility.

President Donald J. Trump's health care overhaul during the first year of his second term reshapes Medicaid, vaccine policies, and drug pricing.

Tobacco use significantly impacts gastric and esophageal cancer outcomes, highlighting the need for targeted public health strategies and smoking cessation efforts.

Lower income and higher social deprivation were associated with increased heart failure and arrhythmia risk in patients with hypertrophic cardiomyopathy.

Food insecurity is associated with a lower rate of annual visits but a higher share of telehealth visits for primary and preventive care.

Telemedicine use in rural areas was associated with a higher likelihood of utilizing preventive services.

The CDC announced a significant change to the childhood immunization schedule that would reduce vaccine recommendations.

Economic stability and social factors significantly influence the risk of pediatric long COVID, highlighting the need for targeted health interventions.

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell carcinoma, and health equity.

New treatments, care gaps, and cardiac monitoring were major focuses in cardiovascular news this year.

Our top 5 obesity articles of 2025 highlight GLP-1 prescribing trends, insurance coverage, co-pay caps, real-world use, and access challenges.

Explore the evolving landscape of drug pricing, reproductive rights, and health policy in 2025, featuring insights on SC pembrolizumab and RFK Jr's hearings.

The most-viewed content focused on the “One Big Beautiful Bill,” the Most Favored Nation drug policy, and other changes under the Trump administration.

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.

Patients with generalized myasthenia gravis face significant barriers to diagnosis, creating the need for improved patient–health care interactions.

From oncology to cardiology, Institute for Value-Based Medicine® conversations highlighted the ways value-based care is reshaping access, equity, and outcomes.

Our top 5 heart failure content of 2025 include FDA approvals, GDMT optimization, risk markers like LBBB and SDOH, and value-based care models improving outcomes in heart failure.

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Heart failure deaths increasingly occur at home or in hospice, but racial, sex, and regional disparities persist in end-of-life care.

Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.

Limiting health-related social needs screening to lower-income areas would reduce screening burdens; however, this study found a 2-stage screening approach based on geography to be suboptimal.